愛朋醫療(300753.SZ)半年度淨利潤預增10%-20%
格隆匯7月12日丨愛朋醫療(300753.SZ)公佈,預計2021年半年度實現營業總收入20833.97萬元至22178.1萬元,同比增長55%-65%;歸屬於上市公司股東的淨利潤3612.3萬元至3940.69萬元,同比增長10%-20%;歸屬於上市公司股東的扣除非經常性損益的淨利潤3549.73萬元至3833.70萬元,同比增長25%-35%。業績變動原因如下:
1. 報吿期內,公司圍繞2021年度經營目標和工作計劃,努力推進各項工作,經營狀況良好。
2. 公司於2021年3月8日披露“關於向激勵對象首次授予限制性股票的公吿”,並於報吿期內確認股權激勵費用1317.41萬元。扣除股權激勵費用影響,報吿期內的淨利潤約4844.18萬元。
3. 報吿期內,預計非經常性損益對公司歸屬於上市公司股東的淨利潤影響金額為20萬元至40萬元,主要為公司取得的政府補助資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.